Search NASA⌕ Search

Engineering topics

Orwoll, Eric S.

Publications and source records attributed to Orwoll, Eric S..

8 records
All sourcesNASA NTRSDOE OSTI
DOE OSTI2020

Proteomic assessment of serum biomarkers of longevity in older men

The biological bases of longevity are not well understood, and there are limited biomarkers for the prediction of long life. We used a high-throughput, discovery-based proteomics approach to identify serum peptides and proteins that were associated with the attainment of longevity in a longitudinal study of community-dwelling men age ≥65 years. Baseline serum in 1196 men were analyzed using liquid chromatography–ion mobility–mass spectrometry, and lifespan was determined during ~12 years of follow-up. Men who achieved longevity (≥90% expected survival) were compared to those who died earlier. Rigorous statistical methods that controlled for false positivity were utilized to identify 25 proteins that were associated with longevity. All these proteins were in lower abundance in long-lived men and included a variety involved in inflammation or complement activation. Lower levels of longevity-associated proteins were also associated with better health status, but as time to death shortened, levels of these proteins increased. Pathway analyses implicated a number of compounds as important upstream regulators of the proteins and implicated shared networks that underlie the observed associations with longevity. Overall, these results suggest that complex pathways, prominently including inflammation, are linked to the likelihood of attaining longevity. This work may serve to identify novel biomarkers for longevity and to understand the biology underlying lifespan.

60 APPLIED LIFE SCIENCES↗
DOE OSTI2019

Proteomic studies of bone and skeletal health outcomes

Proteins are an essential part of essentially all biological processes, and there is enormous variation in protein forms and concentrations that is not reflected in DNA or RNA. Recently there have been rapid advances in the ability to measure protein sequence, modification and concentration, particularly with methods based in mass spectrometry. Global measures of proteins in tissues or in the circulation provide a broad assessment of the proteome that can be extremely useful for discovery, and targeted proteomic measures can yield specific and sensitive assessments of specific peptides and proteins. While most proteomic measures are directed at the detection of consensus peptide sequences, mass spectrometry based proteomic methods also allow a detailed examination of the peptide sequence differences that result from genetic variants and that may have important effects on protein function. In evaluating proteomic data, a number of analytical considerations are important, including an understanding of missing data, the challenge of multiple testing and replication, and the use of rapidly evolving methods in systems biology. While proteomics has not yet had a major impact in skeletal research, interesting recent research has used these approaches in the study of bone cell biology and the discovery of biomarkers of skeletal disorders. Proteomics can be expected to have an increasing influence in the study of bone biology and pathophysiology

Proteomic, Bone↗
DOE OSTI2018

Determination of free 25(OH)D concentrations and their relationships to total 25(OH)D in multiple clinical populations

Context The optimal measure of vitamin D status is unknown. Objective To directly measure circulating free 25-hydroxyvitamin D [25(OH)D] concentrations and relationships to total 25(OH)D in a clinically diverse sample of humans. Design Cross-sectional analysis. Setting Seven academic sites. Patients A total of 1661 adults: healthy (n = 279), prediabetic (n = 479), outpatients (n = 714), cirrhotic (n = 90), pregnant (n = 20), nursing home resident (n = 79). Interventions Merge research data on circulating free 25(OH)D (directly-measured immunoassay), total 25(OH)D (liquid chromatography/tandem mass spectrometry), D-binding protein [DBP; by radial (polyclonal) immunodiffusion assay], albumin, creatinine, intact parathyroid hormone, and DBP haplotype. Main outcome measures Distribution of free 25(OH)D (ANOVA with Bonferroni correction for post hoc comparisons) and relationships between free and total 25(OH)D (mixed-effects modeling incorporating clinical condition, DBP haplotype with sex, race, estimated glomerular filtration rate (eGFR), body mass index (BMI), and other covariates). Results Free 25(OH)D was 4.7 ± 1.8 pg/mL (mean ± SD) in healthy persons and 4.3 ± 1.9 pg/mL in outpatients, with levels of 0.5 to 8.1 pg/mL and 0.9 to 8.1 pg/mL encompassing 95% of healthy persons and outpatients, respectively. Free 25(OH)D was higher in patients with cirrhosis (7.1 ± 3.0 pg/mL; P < 0.0033) and nursing home residents (7.9 ± 2.1 pg/mL; P < 0.0033) than in other groups and differed between whites and blacks (P < 0.0033) and between DBP haplotypes (P < 0.0001). Mixed-effects modeling of relationships between free and total 25(OH)D identified clinical conditions (patients with cirrhosis > nursing home residents > patients with prediabetes > outpatients > pregnant women) and BMI (lesser effect) as covariates affecting relationships but not eGFR, sex, race, or DBP haplotype. Conclusions Total 25(OH)D, health condition, race, and DBP haplotype affected free 25(OH)D, but only health conditions and BMI affected relationships between total and free 25(OH)D. Clinical importance of free 25(OH)D needs to be established in studies assessing outcomes.

Schwartz, Janice B.↗
DOE OSTI2018

High-throughput serum proteomics for the identification of protein biomarkers of mortality in older men

The biological perturbations associated with incident mortality are not well elucidated, and there are limited biomarkers for the prediction of mortality. In this work we used a novel high throughput proteomics approach to identify serum peptides and proteins associated with 5 year mortality in community dwelling men age >65 years who participated in a longitudinal observational study of musculoskeletal aging (Osteoporotic Fractures in Men: MrOS). In a discovery phase, serum specimens collected at baseline in 2473 men were analyzed using liquid chromatography-ion mobility-mass spectrometry, and incident mortality in the subsequent 5 years was ascertained by tri-annual questionnaire. Rigorous statistical methods were utilized to identify 56 peptides (31 proteins) that were associated with 5-year mortality. In an independent replication phase, selected reaction monitoring was used to examine 21 of those peptides in baseline serum from 750 additional men; 81% of those peptides remained significantly associated with mortality. Mortality-associated proteins included a variety involved in inflammation or complement activation; several have been previously linked to mortality (e.g. C reactive protein, alpha 1-antichymotrypsin) and others are not previously known to be associated with mortality. Other novel proteins of interest included pregnancy-associated plasma protein, VE cadherin, leucine-rich α-2 glycoprotein 1, vinculin, vitronectin, mast/stem cell growth factor receptor and Saa4. A panel of peptides improved the predictive value of a commonly used clinical predictor of mortality. Overall, these results suggest that complex inflammatory pathways, and proteins in other pathways, are linked to 5-year mortality risk. This work may serve to identify novel biomarkers for near term mortality.

60 APPLIED LIFE SCIENCES↗
DOE OSTI2017

Identification of Hip BMD Loss and Fracture Risk Markers Through Population-Based Serum Proteomics: HIP BMD LOSS & FRACTURE RISK MARKERS BY POPULATION-BASED SERUM PROTEOMICS

Accelerated bone loss significantly increases the risk of osteoporosis and fracture. The mechanisms underlying bone loss remain incompletely understood, and there are few available biomarkers. We utilized a novel proteomics approach to identify serum peptides and proteins associated with bone loss in 1967 older men who were randomly chosen from the Osteoporotic Fracture in Men Study (MrOS study) (age ≥ 65 yrs). Men had 2-3 measures of femoral neck BMD over an average follow-up of 4.6 years. Change in BMD was estimated and then categorized into three groups: maintained BMD (n=453), expected loss (n=1185) and accelerated loss (n=237). A liquid chromatography–ion mobility separation-mass spectrometry (LC-IMS-MS) proteomics platform was used to identify and quantify peptides from serum proteins. The whole cohort was randomly divided into discovery (N= 960) and validation (N= 915) sub-cohorts. Linear regression models and a random forest approach were used to discover differentially abundant individual peptides and a proteomic signature that distinguished individuals with accelerated bone loss from those who maintained BMD. Network analyses were performed using the MetaCore knowledgebase. We identified 12 peptides that were associated with BMD loss in both discovery (P< 0.1 FDR) and replication sub-cohorts (P<0.05). Those 12 peptides mapped to the following proteins: ALS, LYVE1, RNAS1, C2, ICOSL, C163A, C7, HEMO, CD14, CERU, CRAC1 and CD59. Meta-analysis of peptidesassociated with bone loss identified 6 additional proteins including GRP78, IGF-2, SHBG, ENPP2, IBP2 and IBP6. We also identified a proteomic signature that was predictive of BMD loss with a discriminative value similar to serum bone marker carboxy-terminal collagen crosslink peptide (CTX). Interestingly, combining the proteomic signature with CTX significantly improved the ability to discriminate men with accelerated loss. In summary, we have identified potential new biomarkers for bone loss that provide a more in depth understanding of its pathophysiology.

59 BASIC BIOLOGICAL SCIENCES↗
DOE OSTI2016

Role of Assay Type in Determining Free 25-Hydroxyvitamin D Levels in Diverse Populations

Serum 25-hydroxyvitamin D (25OHD) is the most frequently used marker of vitamin D status. Low 25OHD is associated with bone loss, fractures {Cauley, 2010 #1516;Ensrud, 2009 #1517}, and other adverse health outcomes {Theodoratou, 2014 #1518}. Most extra renal tissues only have access to free 25OHD, and free 25OHD concentration is thus a plausible biomarker of 25OHD availability and function {Johnsen, 2014 #1443;Chun, 2014 #1343}. Stronger associations with free or bioavailable 25OHD than with total 25OHD were reported for serum calcium, parathyroid hormone (PTH) {Bhan, 2012 #1124} and bone mineral density (BMD) {Powe, 2011 #1129}. These findings have led to the suggestion that free or bioavailable 25OHD may provide a more clinically relevant measure of tissue 25OHD availability and vitamin D status {Powe, 2013 #1369; Holick NEJM 2013 editorial}. The US Preventive Services Task Force (LeFevre 2015) recently pointed to the gap in research regarding bioavailable and free 25OHD and noted the possibility that these may be better markers of tissue 25OHD availability. Free 25OHD is conventionally calculated from the concentrations of total 25OHD, vitamin D binding protein (DBP) and albumin, with or without a factor accounting for DBP genotype-specific binding affinities {Bouillon, 1981 #1207;Chun, 2012 #1143; Powe, 2011 #1129;Johnsen, 2014 #1443}. DBP—or Group specific component (GC) {Hirschfeld, 1959 #1468}—polymorphisms (rs4588 and rs7041) give rise to three major polymorphic isoforms of DBP, GC-1F, GC-1S and GC-2, the frequencies of which differ globally, with GC-1F alleles more common in populations of African descent {Kambou, 1986 #1122}. Although DBP is a primary component of free and bioavailable 25OHD calculations, substantial variation in DBP between assays has been noted (Powe suggest to cite here previous publications as in previous version of this Ms). Using DBP measured by a monoclonal antibody Powe et al. {Powe, 2013 #1369} concluded that calculated free 25OHD in African-Americans was equal or higher than in US whites, questioning the implications of low total 25OHD concentrations in African Americans (Holick 2013). This idea gained widespread attention in medical and lay press {LeFevre, 2015 #1598; Bhan, 2014 #1485; Durazo-Arvizu, 2014 #1519}, and many others) and may have important implications for nutrional supplementation policy. To better understand the importance of free 25OHD estimates, and its racial differences, we conducted studies in cohorts based in the US, UK and The Gambia that included participants of African and European ancestry known to differ in GC genotype distribution. We characterized the molecular forms of circulating DBP through comparison of several DBP assays and DBP peptide proteomic analysis, to obtain both calculated and directly measured free 25OHD by geographical region, race and GC genotype.

Environmental Molecular Sciences Laboratory↗
DOE OSTI2013

Protein Co-Expression Network Analysis (ProCoNA)

Biological networks are important for elucidating disease etiology due to their ability to model complex high dimensional data and biological systems. Proteomics provides a critical data source for such models, but currently lacks robust de novo methods for network construction, which could bring important insights in systems biology. We have evaluated the construction of network models using methods derived from weighted gene co-expression network analysis (WGCNA). We show that approximately scale-free peptide networks, composed of statistically significant modules, are feasible and biologically meaningful using two mouse lung experiments and one human plasma experiment. Within each network, peptides derived from the same protein are shown to have a statistically higher topological overlap and concordance in abundance, which is potentially important for inferring protein abundance. The module representatives, called eigenpeptides, correlate significantly with biological phenotypes. Furthermore, within modules, we find significant enrichment for biological function and known interactions (gene ontology and protein-protein interactions). Biological networks are important tools in the analysis of complex systems. In this paper we evaluate the application of weighted co-expression network analysis to quantitative proteomics data. Protein co-expression networks allow novel approaches for biological interpretation, quality control, inference of protein abundance, a framework for potentially resolving degenerate peptide-protein mappings, and a biomarker signature discovery.

Environmental Molecular Sciences Laboratory↗